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tal for Sick Children, reviews 70 charts representing healthy chil-
dren who had strabismus surgery and were given ondansetron
or dimenhydrinate prophylactically. Cost-consequence analysis 
is used to compare costs and outcomes. Cost information was
obtained from the ﬁnance department and the hospital phar-
macy. Cost items include the acquisition cost of the antiemetics,
the cost of administering the agents, the cost length of stay in
the post anesthetic care unit (PACU) and the cost of an episode
of emesis, including laundry expense, materials, nursing time,
housekeeping time and rescue treatment. The outcome measure
used to determine the effectiveness of the antiemetics is the
number of POV-free patients. This represents patients that did
not experience POV that would have otherwise done so without
the prophylactic administration of an antiemetic. RESULTS: In
an adjusted cohort of 100, the number of POV-free patients 
was 45.3 for ondansetron and 38.2 for dimenhydrinate. The
costs per patient were CAD$185.34 for ondansetron and
CAD$232.34 for dimenhydrinate. The length of stay in the
PACU represented over 97% of total costs, and the mean lengths
of stay in the PACU for ondansetron and dimenhydrinate were
signiﬁcantly different, 3.43 and 4.41 hours, respectively. CON-
CLUSION: Ondansetron is more effective in reducing POV and
less expensive than dimenhydrinate. However, the dominance
ondansetron offers over dimenhydrinate is dependent on the
length of stay in the PACU. This study should serve as a pilot
for a larger scale investigation on the correlation between the
length of stay in the PACU and the antiemetic agent used.
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OBJECTIVE: To assess trends in UK GP consultations and pre-
scribing according to BMI classiﬁcation. METHODS: The 
DIN-LINK longitudinal patient database comprises 1.5 million
anonymised medical records from GP practices across Great
Britain. This analysis was based on a cohort of 75,738 DIN-
LINK patients, with BMI status recorded, who had seen their GP
in the year ending August 2004. Patients were grouped accord-
ing to three BMI classiﬁcations: normal (BMI < 25), overweight
(25–30) and obese (>30). We examined the mean number of con-
sultations per patient and the lengths of these consultations in
the three groups. The number and type of prescriptions issued
were also measured. RESULTS: The mean number of consulta-
tions per patient increased as patients’ BMI increased from
normal to obese. Patients with a BMI below 25 saw their GP a
mean 6.4 times [SD 36.5] during the year; this was signiﬁcantly
lower than patients who were overweight (7.5 [35.5]). Patients
classiﬁed as obese had the highest mean number of consultations
at 8.7 [35.3]. This trend was repeated when the number of pre-
scriptions issued per consultation was investigated. In the normal
BMI group a mean 0.87 prescriptions were issued per consulta-
tion, increasing to 0.99 for the overweight individuals; this rose
again to 1.17 in the obese group. Over the course of the year,
obese patients were issued with a mean 10.3 prescriptions,
almost twice as many as normal BMI patients (mean 5.6). There
appeared to be only slight increases in the lengths of consulta-
tions as BMI classiﬁcation increased from normal to obese.
CONCLUSION: Our preliminary analysis shows that patients
with a higher BMI are likely to visit their GP more frequently,
and be issued with more prescriptions, than those of normal
weight. The length of a consultation, however, does not appear
to be inﬂuenced greatly by BMI status.
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OBJECTIVES: In patients with type-1 diabetes, poor glycemic
control is associated with increased risk of complications. A
recent clinical study provided evidence that basal/bolus treat-
ment with insulin detemir+insulin aspart (IDet/IAsp) improved
HbA1c (0.22%-points lower after 18 weeks), reduced risk of
hypoglycemic events (by 21%), and decreased body mass index
(BMI) (-0.3kg .m-2) in comparison to neutral protamine Hage-
dorn insulin+human soluble insulin (NPH/HSI). The aim of this
study was to evaluate the long-term impact of these short-term
clinical beneﬁts in patients with type-1 diabetes in the Dutch
setting. METHODS: We used a validated computer simulation
model (CORE Diabetes Model) to project long-term clinical and
cost outcomes in patients receiving IDet/IAsp or NPH/HSI based
on the clinical study ﬁndings. Standard Markov sub-models were
combined to simulation the incidence and progression of com-
plications (cardiovascular disease, neuropathy, renal and eye
disease). Transition probabilities and HbA1c-dependent adjust-
ments were derived from published sources. Baseline cohort
characteristics and treatment effect data were based on the clin-
ical study. Direct costs were retrieved from published sources and
projected over patient lifetimes from a Dutch National Health
Care perspective. Costs and clinical beneﬁts were discounted 
at 4% per annum. RESULTS: IDet/IAsp treatment was associ-
ated with fewer diabetes-related complications, improved life
expectancy (0.15 life years gained) and quality-adjusted life
expectancy (0.10 QALYs gained) compared to NPH/HSI. Mean
total lifetime costs were 872€ per patient higher with IDet/IAsp,
leading to incremental cost-effectiveness ratios (ICERs) of 5813€
per life year and 8720€ per QALY gained. CONCLUSION:
Short-term clinical beneﬁts in glycemic control, hypoglycemic
event rates and BMI associated with IDet/IAsp basal/bolus
therapy were projected to lead to fewer complications, and
improved life expectancy and quality-adjusted life expectancy
over patient lifetimes compared to NPH/HSI. This resulted in
ICERs for IDet/IAsp versus NPH/HSI in the range considered to
represent excellent value for money.
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OBJECTIVES: Obesity adjustments may have a substantial
effect on models of long-term cost-effectiveness of intensive
lifestyle intervention to prevent type -2 diabetes (T2DM). The
objectives of this study were to: 1) design a long-term cost-
effectiveness model to evaluate the use of lifestyle intervention
to prevent progression from impaired glucose tolerance (IGT) to
T2DM; and 2) to analyze the effect of obesity adjustments for
mortality and costs on the model. METHODS: Markov models
were developed based on the DPP results incorporating the states
of normal glucose tolerance (NGT), IGT, T2DM and death.
Transition probabilities were derived from DPP and current lit-
